Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus TYRUKO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus TYRUKO.
IMPOYZ vs TYRUKO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
Tyr kinase inhibitor that selectively inhibits the activity of the enzyme tyrosine kinase, thereby blocking the phosphorylation and activation of downstream signaling pathways involved in cell proliferation and survival.
100 mg orally twice daily
TYRUKO (tirzepatide) subcutaneous injection: initial dose 2.5 mg once weekly for 4 weeks, then 5 mg once weekly; may increase in 2.5 mg increments after at least 4 weeks on current dose up to maximum 15 mg once weekly.
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 28 hours; approximately 5 days to steady-state.
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Primarily renal (70% as unchanged drug) and fecal (22% as metabolites).
Category C
Category C
Unknown
Unknown